Dotarizin

Dotarizin
(IUPAC) ime
	1-[difenilmetil]-4-[3-(2-fenil-1,3-dioksolan-2-il)propil]piperazin
Klinički podaci
Identifikatori
CAS broj	84625-59-2
ATC kod	nije dodeljen
PubChem	55285
UNII	IO7663S6D3
Hemijski podaci
Formula	C29H34N2O2
Mol. masa	442,592 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C29H34N2O2/c1-4-11-25(12-5-1)28(26-13-6-2-7-14-26)31-21-19-30(20-22-31)18-10-17-29(32-23-24-33-29)27-15-8-3-9-16-27/h1-9,11-16,28H,10,17-24H2 ; Key: LRMJAFKKJLRDLE-UHFFFAOYSA-N
Sinonimi	Dotarizine
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Dotarizin je lek koji se koristi za tretman migrene.^[3] On deluje kao blokator kalcijumovog kanala,^[4] antagonist 5HT_2A receptora, i u manjoj meri 5HT_1A i 5HT_2C receptora.^[5]^[6] On ima antimigrenski efekat jer deluje kao vazodilatator,^[7]^[8] i zato što ima izvesno anksiolitičko dejstvo.^[9] Dotarizin blokira amneziju proizvedenu elektrokonvulzivnim šokom kod životinja.^[10]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). „Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility”. European Journal of Pharmacology 411 (3): 289–99. DOI:10.1016/S0014-2999(00)00897-9. PMID 11164387.
↑ Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). „Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells”. European Journal of Pharmacology 481 (1): 41–50. DOI:10.1016/j.ejphar.2003.09.013. PMID 14637173.
↑ Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). „Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration”. Methods and findings in experimental and clinical pharmacology 19 (5): 343–50. PMID 9379783.
↑ Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). „Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors”. European Journal of Pharmacology 332 (2): 183–93. DOI:10.1016/S0014-2999(97)01073-X. PMID 9286620.
↑ Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). „The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia”. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 36 (2): 101–8. PMID 9757621.
↑ Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). „Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine”. Journal of the neurological sciences 175 (1): 13–6. DOI:10.1016/S0022-510X(00)00275-6. PMID 10785251.
↑ Petkov, VD; Belcheva, S; Konstantinova, E (1995). „Anxiolytic effects of dotarizine, a possible antimigraine drug”. Methods and findings in experimental and clinical pharmacology 17 (10): 659–68. PMID 9053586.
↑ Lazarova, M; Petkova, B; Petkov, VD (1995). „Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats”. Methods and findings in experimental and clinical pharmacology 17 (1): 53–8. PMID 7623521.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). „Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility”. European Journal of Pharmacology 411 (3): 289–99. DOI:10.1016/S0014-2999(00)00897-9. PMID 11164387.

[4] Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). „Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells”. European Journal of Pharmacology 481 (1): 41–50. DOI:10.1016/j.ejphar.2003.09.013. PMID 14637173.

[5] Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). „Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration”. Methods and findings in experimental and clinical pharmacology 19 (5): 343–50. PMID 9379783.

[6] Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). „Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors”. European Journal of Pharmacology 332 (2): 183–93. DOI:10.1016/S0014-2999(97)01073-X. PMID 9286620.

[7] Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). „The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia”. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 36 (2): 101–8. PMID 9757621.

[8] Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). „Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine”. Journal of the neurological sciences 175 (1): 13–6. DOI:10.1016/S0022-510X(00)00275-6. PMID 10785251.

[9] Petkov, VD; Belcheva, S; Konstantinova, E (1995). „Anxiolytic effects of dotarizine, a possible antimigraine drug”. Methods and findings in experimental and clinical pharmacology 17 (10): 659–68. PMID 9053586.

[10] Lazarova, M; Petkova, B; Petkov, VD (1995). „Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats”. Methods and findings in experimental and clinical pharmacology 17 (1): 53–8. PMID 7623521.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]